Showing 6,841 - 6,860 results of 9,864 for search '"drug"', query time: 0.09s Refine Results
  1. 6841

    Meta-analysis of nifedipine and enalapril combination therapy for hypertensive patients with coronary heart disease: A systematic review and meta-analysis by Kun Wang, Wenchao Ma, Leina Sun, Fangcheng Su

    Published 2025-01-01
    “…To analyze and assess the clinical impact of nifedipine combined with enalapril on hypertension complicated with coronary heart disease, and provide evidence for rational drug use in clinic. Methods: We employed a revised version of the Jadad scale to assess the quality of the research literature following a rigorous screening process. …”
    Get full text
    Article
  2. 6842

    Computer simulation of the spatial structure of MUC 1 peptides capable of inhibiting apoptosis by N. V. Ivanisenko, I. N. Lavrik, V. A. Ivanisenko

    Published 2016-01-01
    “…Identification of new effective inhibitors of apoptosis is an important task for drug development for treatment of a number diseases including neurogenerative diseases. …”
    Get full text
    Article
  3. 6843

    Association between polypharmacy and falls in older adults: a longitudinal study from England by Nafeesa N Dhalwani, Melanie J Davies, Kamlesh Khunti, Harini Sathanapally, Radia Fahami, Sam Seidu

    Published 2017-10-01
    “…The rate of falls was 21% higher in people with polypharmacy compared with people without polypharmacy (adjusted IRR 1.21, 95% CI 1.11 to 1.31). Using ≥4 drugs threshold the rate of falls was 18% higher in people with polypharmacy compared with people without (adjusted IRR 1.18, 95% CI 1.08 to 1.28), whereas using ≥10 drugs threshold polypharmacy was associated with a 50% higher rate of falls (adjusted IRR 1.50, 95% CI 1.34 to 1.67).Conclusions We found almost one-third of the total population using five or more drugs, which was significantly associated with 21% increased rate of falls over a 2-year period. …”
    Get full text
    Article
  4. 6844

    Comparative Outcomes of Meropenem–Vaborbactam vs. Ceftazidime–Avibactam Among Adults Hospitalized with an Infectious Syndrome in the US, 2019–2021 by Marya D. Zilberberg, Brian H. Nathanson, Mark A. Redell, Kate Sulham, Andrew F. Shorr

    Published 2025-01-01
    “…Fewer than one-third of all patients received the respective drug within 2 days of the onset of the index infection (30.6% MEV vs. 33.0% CZA, <i>p</i> = 0.313). …”
    Get full text
    Article
  5. 6845

    Comprehensive Pan-Cancer Analysis and Functional Studies Reveal SLC2A6 as a Ferroptosis Modulator in Hepatocellular carcinoma by Guohong Yan, Hailian Huang, Ziyan Lu, Meifeng Chen, Xiang Wang, Pei Zhong, Chongjiu Qin, Shutian Mo, Chuangye Han, Xiaoling Luo, Xinping Ye

    Published 2025-01-01
    “…This study utilized multiple databases to investigate the relationship between SLC2A6 expression and clinical stage, methylation status, drug sensitivity, immune infiltration, and immune checkpoint regulation. …”
    Get full text
    Article
  6. 6846

    Sustainable and smart multi-analyte HPTLC determination of tolperisone HCl together with three pain killers using smartphone camera as a detector: Comparative study with benchtop d... by Mohamed Rizk, Emad Ramzy, Safaa Toubar, Amr M. Mahmoud, Marwa I. Helmy

    Published 2025-08-01
    “…In this study, we developed a novel and cost-effective method for the simultaneous determination of four drugs (Tolperisone HCl (TOLP), aceclofenac(ACEC), Paracetamol (PARA), and etodolac (ETOD)). …”
    Get full text
    Article
  7. 6847

    The O-glycosyltransferase C1GALT1 promotes EWSR1::FLI1 expression and is a therapeutic target for Ewing sarcoma by Shahid Banday, Alok K. Mishra, Romana Rashid, Tianyi Ye, Amjad Ali, Junhui Li, Jason T. Yustein, Michelle A. Kelliher, Lihua Julie Zhu, Sara K. Deibler, Sunil K. Malonia, Michael R. Green

    Published 2025-02-01
    “…Factors that promote EWSR1::FLI1 expression, and thus whose inhibition would reduce EWSR1::FLI1 protein levels and function, are potential drug targets. Here, using genome-scale CRISPR/Cas9 knockout screening, we identify C1GALT1, a galactosyltransferase required for the biosynthesis of many O-glycoproteins, as a factor that promotes EWSR1::FLI1 expression. …”
    Get full text
    Article
  8. 6848

    Predicting Outcomes in Esophageal Squamous Cell Carcinoma Using scRNA‐Seq and Bulk RNA‐Seq: A Model Development and Validation Study by Jiaqi Zhang, Shunzhe Song, Yuqing Li, Aixia Gong

    Published 2025-01-01
    “…Compared with LRG, HRG indicated poor survival and decreased drug sensitivity. Additionally, the immune microenvironment and pathway enrichment were different between the two groups. …”
    Get full text
    Article
  9. 6849

    Ambulatory Intravenous Antibiotic Therapy in Quebec: The Hôpital Charles LeMoyne Experience in 1996 by Laurent Delorme, Charles Frenette, Isabelle Le Corre, Julie Duchesne, Carole Delorme, Pauline Plourde

    Published 2000-01-01
    “…Ceftriaxone and vancomycin were most commonly used for long term therapy. The Drug acquisition antibiotic cost was $73,117 but constituted only 20% of the total outpatient intravenous antibiotic therapy cost. …”
    Get full text
    Article
  10. 6850
  11. 6851

    Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis by Francisco Rodríguez, Daniel Samacá-Samacá, Claudia Hernández-Castillo, Laura Prieto-Pinto, Carolina Sardi, Hugo Ocampo, Joshua Kock, Fabián Hernández

    Published 2024-05-01
    “…Faricimab showed a comparable safety profile regarding the risk of ocular adverse events and serious ocular adverse events (SOAE), except for the comparison with brolucizumab quarterly, in which faricimab showed a significant reduction for SOAE risk.Conclusion Faricimab showed a comparable clinical benefit in efficacy and safety outcomes, with a reduction in annual injections compared with fixed and flexible anti-VEGF drug regimens, representing a valuable treatment option for nAMD patients.PROSPERO registration number CRD42023394226.…”
    Get full text
    Article
  12. 6852

    Comparative Efficacy and Safety of Targeted Therapies for Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Network Meta-Analysis by Yusi Chen, Fang Li, Jun Luo, Jingyuan Chen, Peng Luo, Jiang Li

    Published 2021-01-01
    “…Sildenafil was identified as the best drug in terms of improving the New York Heart Association/World Health Organization functional class with a probability of 87.3%. …”
    Get full text
    Article
  13. 6853

    Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease by H. Trimarchi, R. Canzonieri, A. Muryan, A. Schiel, A. Araoz, M. Paulero, J. Andrews, T. Rengel, M. Forrester, F. Lombi, V. Pomeranz, R. Iriarte, E. Zotta

    Published 2016-01-01
    “…Microhematuria and subsequently proteinuria are hallmarks of kidney involvement, which are due to primary basement membrane alterations that mainly cause endothelial thrombosis and podocyte contraction and ulterior irreversible detachment. Commonly drug-based approaches include angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, which are employed to reduce proteinuria and thus retard kidney disease progression and cardiovascular morbidity and mortality. …”
    Get full text
    Article
  14. 6854

    Antiallodynic Effects of Cannabinoid Receptor 2 (CB2R) Agonists on Retrovirus Infection-Induced Neuropathic Pain by Wen S. Sheng, Priyanka Chauhan, Shuxian Hu, Sujata Prasad, James R. Lokensgard

    Published 2019-01-01
    “…Diverse types of neuropathic pain respond differently to standard drug intervention, and little is currently known regarding the effects of modulation through CB2Rs. …”
    Get full text
    Article
  15. 6855

    Role of Inflammation and Motility Disorders in the Development, Course and Consequences of Functional Gastrointestinal and Biliary Tract Diseases (Literature Review and Expert Pane... by V. T. Ivashkin, D. S. Bordin, T. L. Lapina, M. A. Livzan, A. V. Okhlobystin, E. A. Poluektova, A. S. Trukhmanov, Yu. P. Uspenskiy, Yu. O. Shulpekova

    Published 2024-10-01
    “…In the treatment of functional diseases of the gastrointestinal tract, trimebutine can be considered as a multitarget agent, since the drug helps to normalize motility, reduces the degree of visceral hypersensitivity, exhibits anti-inflammatory and neuroregenerative effects, and can also increase the effectiveness of treatment of concomitant diseases.…”
    Get full text
    Article
  16. 6856

    Association between medication adherence and disease outcomes in patients with hepatitis B-related cirrhosis: a population-based case–control study by Vivian Chia-Rong Hsieh, Kuo-Yu Fu, Meng-Lun Hsieh, Jou-An Chen

    Published 2022-06-01
    “…For patients with and without mortality, drug adherence is ubiquitously higher in the alive group regardless of follow-up length: 1-year MPR (0.62±0.44 vs 0.50±0.51), 6-month MPR (0.78±0.62 vs 0.69±0.72) and 3-month MPR (0.97±0.91 vs 0.96±1.12). …”
    Get full text
    Article
  17. 6857

    Identification and functional analysis of energy metabolism and pyroptosis-related genes in diabetic nephropathy by Shan He, Jian Ye, Yu Wang, Lu yang Xie, Si Yi Liu, Qin kai Chen

    Published 2025-02-01
    “…Additionally, mRNA-miRNA, mRNA-drug, and mRNA-transcription factor (TF) interaction networks were constructed. …”
    Get full text
    Article
  18. 6858

    Lentinan Attenuates Damage of the Small Intestinal Mucosa, Liver, and Lung in Mice with Gut-Origin Sepsis by Zhongshen Kuang, Tingting Jin, ChangYi Wu, Yanan Zong, Panpan Yin, WangYu Dong, Xue Lin, WeiYan You, Chenlong Zhang, Lijie Wang, Yongying Liu, Shan Ren, Jiangwen Yin, Hang Xu

    Published 2021-01-01
    “…The mice were randomly divided into six groups: sham operation group (sham), gut-origin sepsis model group (CLP), ulinastatin-positive drug control group (UTI), lentinan low concentration group (LTN-L, 5 mg/kg), lentinan medium concentration group (LTN-M, 10 mg/kg), and lentinan high concentration group (LTN-H, 20 mg/kg). …”
    Get full text
    Article
  19. 6859

    Case report: Bevacizumab-induced cerebrovascular events: a case series report and literature review by Ke Chen, Boyang Jiang, Boyang Jiang, Huiping Yan, Huiping Yan, Liu Yang, Liu Yang, Zheling Chen, Zheling Chen

    Published 2025-02-01
    “…Bevacizumab is a humanized anti-VEGF drug. By binding to VEGF, it loses the opportunity to activate VEGFR and then plays an anti-angiogenic role. …”
    Get full text
    Article
  20. 6860